The global neuromuscular disease therapeutics market is projected to grow by $13.73 billion between 2025 and 2029, according ...
San Francsiscan liver specialist 89bio (Nasdaq: ETNB) has secured $250 million through a public stock offering, following a ...
In this Expert View column, Abbas Kazimi, chief business officer of Nimbus Therapeutics, discusses the advantages of a ...
The use of the ESMP will become mandatory for MAHs and NCAs as of Sunday, February 2. The platform is a key requirement of ...
Swiss pharm giant Roche today announced that Wafaa Mamilli will join the company as chief digital technology officer (CDTO), ...
Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has ...
In an important regulatory win for Denmark’s Novo Nordisk, the US Food and Drug Administration (FDA) yesterday approved ...
Israeli generics giant Teva Pharmaceutical Industries today reported results for the year and the quarter ended December 31, ...
A damaging trial failure in December wiped 70% off the share price of BioAge Labs, a US biopharma developing therapeutic ...
Switzerland-based Lonza Group was trading nearly 3% lower by lunchtime Wednesday after presenting its financial results for ...
US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...
VIVO, a fast-growing early-stage German contract research organization (CRO) has acquired two clinical research units from Clinical Research Services (CRS), in Mannheim and Kiel, Germany, for a total ...